Stockscreener 앱 받기
6.60
1.35%
-0.09
시간 외 거래:
6.65
0.05
+0.76%
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Raymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Charles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Bank of New York Mellon Corp Purchases 4,557 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Jefferies cuts Phathom Pharmaceuticals target to $13 By Investing.com - Investing.com UK
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating - Marketscreener.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from Brokerages - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com Australia
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St
Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks
Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum - TipRanks
H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com
Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance
Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks
Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks
Stifel maintains Buy on Phathom stock with $28 target - Investing.com India
Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa
Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 By Investing.com - Investing.com Canada
(PHAT) Investment Analysis and Advice - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat
Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World
Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times
Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan
How to Take Advantage of moves in (PHAT) - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN
0.39%
0.34%
자본화:
|
볼륨(24시간):